vs
Side-by-side financial comparison of Scinai Immunotherapeutics Ltd. (SCNI) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
Scinai Immunotherapeutics Ltd. is the larger business by last-quarter revenue ($773.0K vs $421.0K, roughly 1.8× SenesTech, Inc.). On growth, Scinai Immunotherapeutics Ltd. posted the faster year-over-year revenue change (172.2% vs -16.0%).
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
SCNI vs SNES — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $773.0K | $421.0K |
| Net Profit | — | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | — | -446.8% |
| Net Margin | — | -428.5% |
| Revenue YoY | 172.2% | -16.0% |
| Net Profit YoY | — | -43.7% |
| EPS (diluted) | — | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $421.0K | ||
| Q3 25 | — | $690.0K | ||
| Q2 25 | $773.0K | $625.0K | ||
| Q1 25 | — | $485.0K | ||
| Q4 24 | — | $501.0K | ||
| Q3 24 | — | $482.0K | ||
| Q2 24 | $284.0K | $459.0K | ||
| Q1 24 | — | $415.0K |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | — | -446.8% | ||
| Q3 25 | — | -195.2% | ||
| Q2 25 | — | -258.2% | ||
| Q1 25 | — | -342.9% | ||
| Q4 24 | — | -250.9% | ||
| Q3 24 | — | -321.0% | ||
| Q2 24 | — | -349.0% | ||
| Q1 24 | — | -444.1% |
| Q4 25 | — | -428.5% | ||
| Q3 25 | — | -188.1% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -343.3% | ||
| Q4 24 | — | -250.5% | ||
| Q3 24 | — | -313.9% | ||
| Q2 24 | — | -345.1% | ||
| Q1 24 | — | -441.4% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | — | $-1.28 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | $-2.07 | ||
| Q2 24 | — | $-3.08 | ||
| Q1 24 | — | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $989.0K | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.9M | $9.6M |
| Total Assets | $11.8M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $10.2M | ||
| Q2 25 | $989.0K | $6.1M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | $3.1M | $2.0M | ||
| Q1 24 | — | $3.6M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.3M | ||
| Q2 25 | $7.9M | $7.0M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | $-7.3M | $3.1M | ||
| Q1 24 | — | $4.6M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | $11.8M | $10.4M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | $14.9M | $4.0M | ||
| Q1 24 | — | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -398.3% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | — | -441.2% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
